



IMPROVING
HEALTHCARE
THROUGH
GENETICS



WHO WE ARE

Our story began in the 1970s with a young student passionate about one thing: DNA. George Church's work set countless genetic discoveries into motion, including the Human Genome Project, the first initiative to map all genes in the human genome.

Dr. Church, along with a group of visionaries and scientists, including leaders from Harvard Medical School's Personal Genome Project, co-founded Veritas with the idea of bringing the benefits of genomic data to millions of people globally.



Veritas is “The Genome Company”, experts in DNA analysis and interpretation, we are committed to continuous innovation through research and education.

OUR MISSION

To transform genetic data into useful information to improve the quality and duration of an individual's life.

WHY ARE GENETICS IMPORTANT IN PREVENTIVE HEALTHCARE MANAGEMENT



86%

86% of people are asymptomatic carriers of a monogenic disease that can be transmitted to their offspring if the partner is a carrier of the same disease.



17%

17% of people have genetic variants that increase the risk of diseases.

20%



Around 20% of sudden cardiac deaths are due to genetic abnormalities.



20%

Up to 20% of cancer cases are related to hereditary factors.

5%



5% of patients are hospitalized for adverse drug reactions.

FROM 'SICK CARE' TO HEALTHCARE

Veritas' preventive genetic services strive to shift traditional patient care from 'Sick Care' to Healthcare through identifying genetic predisposition before biological onset.



PREVENTIVE MEDICINE

myGenome – Whole Genome Sequencing based comprehensive genetic risk screening analysis designed for healthy individuals.

myGeneticRisk – Combined hereditary risk screening analysis of cardiovascular disease and cancer.

myHealthScore – Multi - Polygenic risk score assessment that provides information regarding patient risk for common multifactorial diseases.

myCardio – Hereditary risk screening analysis of inherited cardiovascular disease.

myCancerRisk - Hereditary risk screening analysis of multiple types of cancer.

Our services include Genetic Counseling supported by a fully certified medical team.





PREGNANCY & EARLY CHILDHOOD

myPrenatal - The most comprehensive non-invasive prenatal test (NIPT) available.

myNewborn - Newborn genetic screening for early onset diseases.

myPrenatalWES – An advanced prenatal diagnostic service that incorporates deletions/duplications analysis and molecular testing.

PregnancyLoss - An advanced test that allows the determination of underlying genetic causes in cases of spontaneous pregnancy loss.

DIAGNOSTIC SERVICES

Veritas provides a full diagnostic portfolio that includes customized Whole Genome Sequencing and Whole Exome Sequencing based panels to meet the specific needs of medical professionals.



VERITAS OPERATES
A NEXT GENERATION
SEQUENCING (NGS)
ISO CERTIFIED
LABORATORY.

Services are conducted in
the Veritas' laboratory in
Spain.

Our scientists are globally
recognized pioneers in
genetic data sequencing
and interpretation.

my Genome

by Veritas

Whole genome sequencing and interpretation service to prevent disease and improve the health of patients. The analysis is designed for individuals proactive in taking care of their health.

- Whole genome sequencing and interpretation **aimed to improve health and prevent diseases.**
- First genetic analysis designed to integrate genomics into a patient's health check-ups, **enabling personalization of medical care.**
- myGenome analyzes the genetic risk of over **650 diseases including cardiovascular disease and cancer.** The objective is to identify genetic predisposition and establish the specific patient approach for early detection or prevention.
- Additionally, information is provided about **risk alleles, carrier status, pharmacogenomics and genetic traits.**
- **The analysis is performed once in a lifetime** and the genetic information is available to offer updates based on the on-going advances of scientific knowledge.
- myGenome includes **genetic counseling before and after the test** to explain the results and establish next steps.



+650

Diseases with
clinical relevance



+225

Carrier
conditions



+150

Drug
response



+15

Multifactorial
diseases



+50

Traits



Ancestry



The data used for the myGenome analysis is sequenced once and can be utilized for future updates as scientific knowledge advances, becoming a resource for life.



Diseases that can be prevented or better managed through early detection, selected by a medical team from the Personal Genome Project and Harvard University.



Clinically important information that can be utilized by a physician to personalize patient healthcare management.



Expert geneticists in variant analysis who perform the interpretation based on the most current scientific knowledge with public, private and the Veritas proprietary database.



Comprehensive report with detailed information that is easy to understand for the patient.



Fully certified genetic counseling in various medical areas. Support to specialists and patients.

my Genetic Risk+

Risk screening for healthy individuals with the goal of preventing common genetic diseases.

A preventive genetic risk screening that allows for a more comprehensive assessment of a patient's risk for common diseases. The analysis includes a combined monogenic and polygenic risk assessment, allowing for the detection of more at-risk individuals who can benefit from preventive medicine strategies tailored to a patient's individual needs.

Monogenic Assessment

- **100 genes** related to **cardiovascular hereditary diseases**
- **40 genes** related to **hereditary cancer**
- Additional **24 genes** to cover **ACMG73 genes** (American College of Medical Genetics and Genomics) related to actionable diseases

Polygenic Assessment

Assessment of a large number of genetic variants, providing the patient risk for the following common diseases:

Cardiovascular disease

>2 million variants

Type 2 diabetes


> 600.000 variants

Breast cancer

> 550.000 variants

Prostate cancer

> 650.000 variants



The analysis provides information about the lifetime risk of cardiovascular disease, type 2 diabetes, breast cancer and prostate cancer.

The assessment is for **healthy adults** (18 years and older) who are **proactive about their healthcare management**.

myHealthScore performs the assessment of a large number of genetic variants, providing the patient risk for the following common diseases:



Cardiovascular disease

>2 million variants



Type 2 diabetes

> 600.000 variants



Breast cancer

> 550.000 variants



Prostate cancer

> 650.000 variants

myHealthScore is a screening test that evaluates millions of common variants throughout the genome to establish the genetic risk of developing certain common diseases, with the goal of preventing or detecting them at an early stage.

my Health Score

Polygenic risk score test that provides information regarding patient risk for common multifactorial diseases.

my Cardio

Genetic screening that determines the patient's risk of developing hereditary cardiovascular disease.

- The analysis is intended for **patients with personal or family history of cardiovascular disease.**
- **myCardio includes the analysis of 100 genes related with hereditary cardiomyopathies** causing arrhythmogenic cardiomyopathy and structural abnormalities.
- myCardio includes **pre and post test genetic counselling** to assess the suitability of the test, explain the results and establish a care plan if necessary.
- Knowing the hereditary risk to develop cardiovascular disease allows the physician to implement specific **patient follow up and discuss different preventive options.**

The test is especially indicated in:



People with suspected or diagnosed cardiovascular pathology.



People with a family history of cardiovascular disease in several family members suggesting a hereditary component.



People who want to know their risk of cardiovascular disease, especially amateur or professional athletes.

- A hereditary genetic risk screening for **patients with personal or family history of cancer.**
- myCancerRisk includes the analysis of **40 genes related with cancer and hereditary cancer syndromes.**
- **Includes pre and post test genetic counselling** to assess the suitability of the test, explain the results and establish next steps.
- Knowing the risk for hereditary cancer allows the physician to establish a specific **patient monitoring program and determine different preventive options.**

	AFC*	ATM*	AXIN2	BAP1	BARD1	BRIP1/A	BRCA1*	BRCA2*	BRIP1	CDH1	CDK4	CDKN2A	CHEK2*	EPCAM*	FLCN	GRB1*	H2X/13	MIF	MLH1*	MLH3	MSH2*	MSH3	MSH4*	MUTHY	NBN	NF1	NTHL1	PALE2*	PKS2*	RAD51	RDLE	ROD1	PTCH1	PTEN*	RAD51C	RAD51D	SMAD4	STK11*	SUFU	TP53*		
Breast	●				●		●	●	●	●			●						●		●				●	●							●	●	●	●	●	●	●	●	●	
Gynecological					●		●	●	●					●					●	●	●	●	●	●	●			●	●					●	●	●	●	●	●	●	●	
Prostate	●						●	●	●				●	●			●		●		●	●	●	●	●			●	●							●	●	●	●	●	●	
Colorectal	●	●	●	●	●	●				●			●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Gastric	●				●					●				●					●	●	●	●	●	●	●	●			●							●	●	●	●	●	●	
Pancreatic	●	●				●	●	●				●		●					●	●	●	●	●	●	●			●	●							●	●	●	●	●	●	
Skin				●			●				●	●	●	●	●		●	●	●	●	●	●	●	●	●			●				●	●	●				●	●	●	●	

my Cancer Risk

Genetic screening that provides information about the patient's risk to develop hereditary cancer.

my Prenatal

The most comprehensive non-invasive prenatal test (NIPT) available.

A comprehensive non-invasive prenatal test that analyses the risk for all aneuploidies performing a genomic study of large CNVs with equivalent resolution to the semi-direct karyotype.

The test is intended for:

- Any pregnant women, **from the 10th week of gestation**
- It can be performed in **single and twin pregnancies**
- Suitable for pregnant women through **assisted reproductive techniques, even in cases of gamete donation**
- The test offers all basics options together with the possibility of screening CNVs (Copy Number Variations) along the fetus' genome, not detected with other screening options.
- Technology improved to issue results even in the presence of low fetal fraction.
- Veritas has internationally recognized experts in both genetic counselling and prenatal diagnosis to support physicians with the assessment of results CE-IVD marked.

myPrenatal GenomeScreen


Trisomy 21 + Fetal sex + Sex chromosomes (X,Y) aneuploidies + Duplications and deletions (CNVs) >7 Mb + Aneuploidies in all autosomal chromosomes

Trisomy 18

Trisomy 13

- The genetic screening is for **newborns without any symptoms of disease**.
- myNewborn is the **most comprehensive whole exome based neonatal genetic screening test available**.
- The test analyzes 406 genes associated with **390 diseases that appear in the first years of life** in order to prevent or detect medical conditions in the early stages of life.
- In most cases the result is negative which provides tranquility. In case of a positive result, the **information is key for an early management of the newborn's healthcare**.
- Scientific studies show that up to **10% of the children could benefit from early detection and management**.
- Most diseases are **treatable** through diet or early intervention.

Classification of the myNewborn pathologies by clinical management



my Newborn

Neonatal genetic screening that analyzes actionable childhood onset genetic diseases, allowing early detection or prevention.

Prenatal WES

Innovative prenatal diagnostic test indicated for pregnancies with risk of presenting a genetic alteration.

- PrenatalWES is a **diagnostic service for pregnancies with fetal structural anomalies** such as cardiac malformations, short femur, increased nuchal translucency, or intrauterine growth restriction, after ruling out the presence of aneuploidies.
- The test is based on fetal **whole exome sequencing enhanced for the detection of CNVs**, allowing the detection of a possible genetic cause in at risk pregnancies with a single technique.
- This approach allows the detection of all possible genetic causes of malformation in one step, avoiding the request of different techniques that would delay the results delivery (array and NGS).
- **Includes pre and post test genetic counselling** to assess the suitability of the test, explain the results and establish next steps.
- It is a diagnostic test that requires an **amniotic fluid or chorionic villus biopsy** sample.

- The test is intended for **pregnancies in which there has been a spontaneous interruption of fetal development**, anembryonic sacs, lack of fetal heartbeat or abortion in progress.
- It can be performed from the 5th week of gestation with a maternal blood sample.
- Both numerical and structural chromosomal abnormalities are the most common cause of miscarriage.

PregnancyLoss screens for:

- Common aneuploidies
- Deletions and duplications (CNVs) >7Mb in autosomal chromosomes
- Aneuploidies in all chromosomes

Pregnancy Loss

Advanced screening test that allows to determine if there is an underlying genetic cause in cases of miscarriage.

Diagnostic Services

**Genome
Dx**

**Exome
Dx**

**Customized
Panels**

Diagnostic services are optimal tools for genetic diagnosis in patients with a complex medical history. Veritas, through whole genome and exome sequencing and interpretation, supports medical professionals in diagnosing rare conditions to assist in the clinical management of patients.



Who are they for?

Recommended for patients with a complex medical history or symptoms that suggests a genetic disease.

The objective of the diagnostic analysis is to identify a patient's condition so that treatment decisions and clinical management options can be determined.



Complete study

It is highly recommended that biological samples from the parents be analyzed if available to support the interpretation of the patient's genomic data.

Veritas is a pioneer in offering the TRIO GENOME study with the aim of maximizing the diagnostic performance of patients.

Genetic counseling provides key information about the interpretation of genetic results and support in making informed clinical decisions about a patients' healthcare management.



Family
planning



During
pregnancy



People with a
family medical
history



People proactive
in their health care
management



People diagnosed
with a genetic
syndrome



People with symptoms
and clinical signs with
suspected genetic origin
without diagnosis



Improving healthcare through genetics

Please contact us for more information
about our portfolio of genetic services

veritasint.com

